Premium
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
Author(s) -
Lee Paula S.,
Teaberry Vanessa S.,
Bland Amy E.,
Huang Zhiqing,
Whitaker Regina S.,
Baba Tsukasa,
Fujii Shingo,
Secord Angeles Alvarez,
Berchuck Andrew,
Murphy Susan K.
Publication year - 2010
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24797
Subject(s) - methylation , ovarian cancer , biology , cpg site , dna methylation , cancer research , cisplatin , serous fluid , microbiology and biotechnology , transcription (linguistics) , gene , cancer , gene expression , genetics , chemotherapy , biochemistry , linguistics , philosophy
We previously found that the gene encoding the Myelin and Lymphocyte protein, MAL , was among the most highly expressed genes in serous ovarian cancers from short‐term survivors (<3 years) relative to those of long‐term survivors (>7 years). In the present study, we have found that this difference in expression is partially attributable to differences in DNA methylation at a specific region within the MAL promoter CpG island. While MAL was largely unmethylated at the transcription start site (Region 1; −48 to +73 bp) in primary serous ovarian cancers, methylation of an upstream region (Region 2; −452 to −266 bp) was inversely correlated with MAL transcription in the primary cancers ( R = −0.463) and ovarian cancer cell lines ( R = −0.444). Following treatment of the OVCA432 cell line with 5‐azacytidine, methylation of Region 2 decreased from 73.3% to 34.7% ( p = 0.007) while Region 1 was unaffected. This was accompanied by a 10‐fold increase in MAL expression. Since MAL transcripts are elevated in tumors from short‐term survivors, all of whom were treated with platinum‐based therapy, MAL may have a role in cisplatin response. We therefore determined the 50% growth inhibitory dose of cisplatin in 30 ovarian cancer cell lines and compared this to MAL expression. MAL transcript levels were higher in the resistant ovarian cell lines ( p = 0.04). MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum‐based drugs in ovarian cancer.